Severe Delayed Hemolysis Associated with Regulated Parenteral Antimalarial Drug (http://wwwnc.cdc.gov/eid/article/21/1/14-0147)

摘要

To the Editor: Intravenous artesunate is recommended by the World Health Organization as first-line treatment for severe malaria. While artemisinin-based therapies are well tolerated, recent studies have reported cases of severe delayed hemolysis after artesunate treatment for malaria ( 1 – 5 ). To date, all reported cases have been associated with the use of artesunate not produced under Good Manufacturing Practice (GMP) standards. The United States and Canada are the only countries that use GMP artesunate, and a recent review concluded that delayed hemolysis may be related to differences in GMP versus non-GMP artemisinins ( 5 ). We report a case of severe delayed hemolysis after administration of GMP artesunate to treat a patient with severe malaria.